BioXcel

Alto Neuroscience

This biopharmaceutical company develops precision medicines for patients with neuropsychiatric conditions by using an artificial intelligence platform to analyse brain-based biomarkers.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

ATAI

This biopharmaceutical company develops psychedelic-based treatments and mental health medicines for patients with neurological and psychiatric disorders, such as treatment-resistant depression and anxiety.

Exin Therapeutics

This company develops an artificial intelligence platform to discover and design neurotherapeutics targeting neural circuits for patients with neurological and neuropsychiatric disorders.

Pangea Botanica

This company develops medicines for neurological and mental health disorders using an artificial intelligence platform to discover neuroactive molecules from medicinal plants.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Pangea Bio

This biotechnology company develops small molecule medicines for neurological and neuropsychiatric disorders using an artificial intelligence platform to identify compounds from natural sources.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.